Amgen Inc. (AMGN)
-NasdaqGS 105.91 
0.29(0.27%) May 24, 4:00PM EDT|After Hours
:
105.91 0.00 (0.00%) May 24, 4:20PM EDT
| Prev Close: | 105.62 |
|---|
| Open: | 104.92 |
|---|
| Bid: | 105.91 x 300 |
|---|
| Ask: | 106.30 x 200 |
|---|
| 1y Target Est: | 112.95 |
|---|
| Beta: | 0.54 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 104.37 - 106.17 |
|---|
| 52wk Range: | 67.61 - 114.95 |
|---|
| Volume: | 2,410,950 |
|---|
| Avg Vol (3m): | 4,204,010 |
|---|
| Market Cap: | 79.43B |
|---|
| P/E (ttm): | 17.93 |
|---|
| EPS (ttm): | 5.91 |
|---|
| Div & Yield: | 1.88 (1.80%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Biotechnology companiesAP(Fri, May 24)
- [video] Nasdaq Check: Valeant-Bausch & Lomb Deal?at CNBC(Fri, May 24)
- Midday Glance: Biotechnology companiesAP(Fri, May 24)
- Investing In Cancer Research Is Worth The Risk: Echo Heat Seeking Alpha(Fri, May 24)
- Early Glance: Biotechnology companiesAP(Fri, May 24)
- Amgen: Financial Analysis And Valuationat Seeking Alpha(Fri, May 24)
- A New Cancer-Killing Virusat Motley Fool(Thu, May 23)
- Amgen to Present at the Deutsche Bank 38th Annual Healthcare ConferencePR Newswire(Thu, May 23)
- A Trio of ETFs Sitting on 30% Gains This YearETF Trends(Thu, May 23)
- Amgen Stock Checkup for Mayat Motley Fool(Thu, May 23)
- 5 Stocks Raising The Drugs Industry Higherat TheStreet(Thu, May 23)
- Halozyme names David Ramsay as CFOAP(Thu, May 23)
- Feel guilty for taking leave? You're not alone.at Fortune(Thu, May 23)
- AMGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of SecurityEDGAR Online(Wed, May 22)
- Can Financial Innovation Unlock a Cure for Cancer?at Motley Fool(Wed, May 22)
Key Statistics
| Forward P/E (1 yr): | 12.82 |
|---|
| P/S (ttm): | 4.54 |
|---|
| Ex-Dividend Date: | 14-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 7.28 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.74 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | 1.55 |
|---|
Business Summary
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the Uni...
View More